What CTA clauses do sites need to consider to mitigate risk when participating with DCTs? This session will evaluate potential risks, such as PI oversight, to help you construct a risk mitigation plan for your site.
PANELISTS Molly Butler, Associate Director, Audit Management, PPD Joseph Kim, Chief Strategy Officer, ProofPilot Adrian McDonald, Director, Site Optimization and Solutions, Illingworth Research Group ( a Syneos Company)
Site Optimization to Maximize Profitability
With inflation and costs at an all time high, it's critical to evaluate your site's fixed costs and identify opportunities to reduce them. This session will share cost-saving methods and how to modify site operations to maximize site efficiency and profitability.
PANELISTS Jane Hiatt, Merck Luis Russo, MD, PhD, CEO, Director, IBPCLIN Care Access Brazil William Smith, MD, CEO, Alliance for Multispecialty Research, LLC
eRegulatory and eSource: The Pros & Cons
As eRegulatory and eSource systems become more common at sites, it is important to understand the differences between electronic and traditional regulatory processes as well as source data collection. This panel will discuss barriers to moving to electronic regulatory and source document platforms and if they are right for your site.
PANELISTS Henry Kravchenko, CEO, Clinical.ly Jeff Smyth, MS, President/Executive Director, TrueBlue Clinical Research
Understanding Different Site Operation Models: Balancing Relationships & Success for Growth
Join us for an open discussion on the pros and cons of site operation models and how they affect relationships with sponsors, CROs, and other sites. How do you differentiate your site so everyone wins? This session will unpack learnings from operating different site models so you can determine the best way to organize your site business.
FACILITATOR Jennifer Byrne, CEO, Javara
PANELIST Justin Bandura, JD, Sr. Associate Director, Strategic Alliance Clinical Development & Operations, Boehringer Ingelheim April Coburn, MLA, Associate Director, Therapeutic Area ICON, Plc Richard Pollack, DPM, MSc, Advisor/Consultant,
Privacy, Data & Protection: What You Need to Know
The need for privacy protection and secure information disclosure for clinical trials is an ongoing challenge. This session will discuss how HIPAA, protected health information (PHI) and personally identifiable information (PII) apply to your site and prepare you for EU privacy regulations that impact sites globally.
FACILITATOR Hans Christian Hoeck, MD, PhD, Founder, TrialCare AG
PANELISTS Al Pacino, General Manager, BlueCloud by HealthCarePoint Michael Swartz, JD, Director Global Site Agreements, Merck
How to Stand Out as a Site & Be Selected for Studies
*BD & Relations
Do you want your site to stand out during feasibility? Come learn from successful sites and sponsors on how to become a partner site of choice. Understand the key elements of the study startup process and get tips and metrics from sponsors and CROs to help improve your site's visibility.
FACILITATOR Barry Lake, CEO & Co-Founder, Devana
PANELISTS Jillian Agnew, RN, CCRC, Senior Clinical Research Nurse, St. Johns Center for Clinical Research Karen McIntyre, MSc Clinical Trials, P, Global Site Alliances, Parexel Lindsey Morales, Associate Director, Clinical Operations, Gilead
The Foundations of Consenting in Modern Times
What do we need to do to assure our patients continue to be consented in the right way, given the tremendous increase in trial complexity? Join us for an engaging discussion as we compare traditional consenting practices with modern consenting needs. Leave this session understanding the basics of consenting effectively and translating that to compliance.
FACILITATOR Tarra Shingler, MS, CCO STUDYKIK
PANELISTS Bella Tukuafu Johnson, President, CEO, Kalo Clinical Research Harpreet Monga, Research Scholar, Clinical Researcher, Neuro Pain Center Dawn Stretlow, MSN, MBA, RN, Associate Director, Client Engagement, Patient ConsentIQVIA Technologies
Financial Implications of Diversity, Equity & Inclusion Strategy
This hot-topic panel discussion focuses on the financial implications of incorporating diversity into your organization's strategy. We know that new diversity requirements will come with financial needs and changes at the site level, and this session will discuss what some of those changes are and how we ensure they are addressed.